The new FDA-approved autoinjector delivers 125mg of subcutaneous (SC) Orencia with push button operation and injection confirmation, helping in reducing the possibility of user errors.
Orencia ClickJect features an ergonomic design and non-slip grip, which provides control for dexterity-compromised patients.
Orencia is claimed to be the only RA biologic that provides three administration options, including IV infusion, prefilled syringe and autoinjector.
The device automatically delivers the full dose of Orencia with one push of a button and the user holding for fifteen seconds.
In addition, the device’s large viewing window and blue indicator allow to confirm the full dose of Orencia has been injected.
Orencia is a prescription medicine indicated to reduce signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA.
Bristol-Myers Squibb US head Chris Boerner said: “Today’s launch of the Orencia ClickJect is an example of our continued commitment to offering patients with moderate to severe rheumatoid arthritis a treatment option that may be appropriate for them, now available as an autoinjector.
“This approval offers more options for healthcare providers and members of the arthritis community to consider when selecting the optimal treatment and administration option for each individual.”
Bristol-Myers Squibb Orencia medical lead Dr Sheila Kelly said: "Through the new Orencia ClickJect, we are able to offer the proven benefits of Orencia in an accurate dose self-injection and provide an additional option for healthcare providers when selecting treatment options for their patients.”
